Sign Out
Each Modified-Release Tablet contains: Trimetazidine Dihydrochloride 35 mg.
Trimetazidine is a cardiovascular drug that acts as an effective anti-anginal agent by modulating cardiac energy metabolism. It is an anti-ischemic metabolic agent that improves myocardial glucose utilization through inhibition of fatty acid metabolism. By preserving the energy metabolism in cells exposed to hypoxia or ischemia, Trimetazidine prevents a decrease in intracellular adenosine triphosphate levels, thereby ensuring the proper functioning of ionic pumps and transmembranous sodium-potassium flow while maintaining cellular homeostasis. Trimetazidine also inhibits the oxidation of fatty acid in blood vessels.
